INTRODUCTION

D
evelopment of lead drug candidates (having potential pharmacological eff ect) derived from combinatorial synthesis has accelerated the drug discovery process. Th ey have emerged as a quick and easy methods provides data on biological parameters like Potency, Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) properties of large number of candidates can be determined simultaneously (1) . However limiting factors for the successful therapeutic application of new drugs is their ability to transport in biological systems namely, over the gastro intestinal tract (GIT), towards the target receptor, or across the blood brain barrier (BBB). Highly standardized invitro models are therefore required for screening of large number of molecules that gives predictive values for these transport processes. But however, absorption process is infl uenced by number of factors such as solubility, membrane partitioning, metabolism and transporters (2) , (3) , (4) . In contrast to less accurate experimentally based insilico predictions of intestinal permeability, done based on their molecular structure, behaviour of molecule with in a biological test system, mechanistic cell lines which gives better data is preferred. Th erefore cell lines have evolved as a tool for understanding and evaluating the permeability characteristics of potential lead drug candidates.
Screening of permeability of lead drugs in lead discovery phase (LD) results from High Th roughput Screening (HTS) which provide data and basis for the further modifi cations of the structure of the molecule in lead optimization phase (LO) which ends with the selection of drug candidate (DC).Hence cell culture models provides a platform for preclinical screening, biopharmaceutical assessments & evaluation of mechanistic purposes (5).
hydrophobic marker molecules, that do not partition into cell membranes (6) . Th e functional characteristics of diff erent cell lines currently used in drug discovery are summarized in Table-1 .
CACO-2 CELL LINE/CELL CULTURE AND TRANSPORT EXPERIMENTS
By virtue of the merits stated in the Table-1 CACO-2 cell line is most widely used to screen intestinal permeability, to know drug absorption, and to study passive and active diff usion transport of drug molecules.
METHODOLOGY (7),(8)
Cell lines used for screening are should be precultivated. Th e generalized culturing and experimental setup for CACO-2 cell model is as follows:
Th e cells are maintained on the fi lter inserts or culture fl asks at 37⁰C in Dulbecco's modifi ed Eagle's medium, 1% non-essential amino acid, 1.5% L-glutamine solution (200mM) and 9% fetal bovine serum and antibiotics under an atmosphere of 5% CO 2 .[Antibiotics-penicillin and streptomycin are used when cells grown on fi lter inserts]. Cultures are checked routinely for mycoplasma contamination. Cells are harvested from cell culture fl asks by trypsinization -with a trypsin (0.25%) + EDTA (0.2%).
For transport studies CACO-2 cells are seeded on to specially designed culture inserts or fi lter inserts. Filter inserts of diff erent membrane material and pore diameter are available. Some commercially available examples are Transwell inserts (Polysorbate; Corning Life sciences (9) and BD Falcon inserts (Polyethylene terepthalate (PET); BD Bioscience (10). CACO-2 cells are directly grown on the fi lter inserts without extracellular collagen coating ,which is required for other cell lines for proper cell attachment and diff erentiation. Cell membrane inserts with narrow pore diameter (0.4μm) are generally used. Large pores results in monolayers growing on both sides of the membrane, resulting in depolarised cells and shall mislead the results. Seeding density should be between 0.5 and 5×10 5 cells/cm 2 . Cells are attached to the fi lters and are grown for 2 to 3 weeks (11), at this stage well diff erentiated monolayer intestinal epithelial cells having morphological and biochemical properties that resemble those of normal intestinal (absorptive) enterocytes are formed.
In drug absorption studies, drug is added to apical (mucosal site) and drug appearance on the basolateral side (serosal) is studied by time .Th ese model also permit experiments carried out in reverse direction (basolateral to apical). Drug absorption experiments are performed at 37⁰C under sink conditions in order to avoid back diff usion. Trans epithelial electrical resistance (TEER) should be measured prior to and after experiment to verify monolayer integrity.
Apparent permeability coeffi cient (P app ) is calculated by equation:
dq/dt -rate of appearance of drug on the receiver side, C do -initial drug concentration on the donor side, A -surface area of the fi lter membrane.
Th is equation is improved by taking in to account the change of donar concentration (C d ),which aff ects driving force for passive diff usion and concentration gradient. Th us the modifi ed equation P app = k x Vr/A. k -change in drug concentration in the receiver chamber (C r-ti /C d-t ) per unit time, C r-ti -concentration on the receiver side at the end of each time interval, C d-ti -average of the donor concentration determined at the beginning and at the end of each time interval, Vr -volume of the receiver chamber, and A -surface area of the fi lter membrane.
AUTOMATED CACO-2 ASSAY
Automated CACO-2 permeability assay is performed using semi or fully automated procedures. Using this system it is possible to obtain a throughput of approximately 400-500 compounds per week. Automated CACO-2 assay systems are commercially available through Tecan (12), BD Bioscience and Bohdan, Mettler Toledo (13). In addition, automated systems for maintenance of cell cultures are commercially available, while totally automated systems for both maintenance and culturing of cells grown on permeable fi lter supports are under development by companies such as Th e Automation Partnership (14).
Solubility of test compounds measured to make correct determination of the permeability coefficient.Test compounds are fi rst prepared in dimethyl sulfoxide (DMSO) solution (1mM) on parent In the robotic systems the basolateral chamber is fi lled with transport buff er, after which donor drug solution is added to apical side of CACO-2 monolayer. Samples are taken immediately from the donor side to determine the initial donor concentration. Th e appearance of compound on the receiver is measured by taking samples from the receiver side at 45 and 120 min. At the end of the experiment, samples are also taken from the donor side in order to measure the change in donor concentration and calculate mass balance (recovery) of the transport process. In general, the samples are collected in deep well 96-well plates, diluted in acetonitrile and then analyzed for drug content by LC/MS. Th e recovery should be kept within limited ranges in order to assure highquality and accurate P app values. Limits for recovery are between 80 and 120%. Recovery % is calculated by
Recovery (%) = (M r-120 + M d-120 /M d-o ) × 100
M r-120 -cumulative amount of drug transported to the receiver side at the end of the experiment (including amount removed in sampling), M d-120 -amount of drug remaining on the donor side at the end of the experiment, and M d-0 -amount of drug on the donor side at the start of the experiment (determined from the initial donor concentration sample).
QUALITY CONTROL AND STANDARDIZATION OF CACO-2 ASSAY
For reproducible and high-quality results, a routine characterization should be performed on each new batch of cell monolayers by measuring TEER and permeability to a paracellular marker such as 14 C-mannitol.Th e morphology and integrity of the monolayers should be examined using Transmission Electron Microscopy (TEM) and Fluorescence microscopy.
Th e following parameters should be standardised (15) Filter supports and growth media.
• 
OPTIMIZATION OF EXPERIMEN-TAL CONDITIONS (16), (17) a) pH
Th e pH in the gastro intestinal tract (GIT) is a very important factor aff ecting drug absorption for ionisable drugs. pH has two main eff ects on drugs: one is to determine the degree of ionization (dissociation) of weak electrolytes and thereby aff ect the passive diff usion of the compound; and the other is to establish a proton gradient as a driving force for some transporters.
Th e pH in the lumen of the human GIT is variable; typically it is pH 1-2 in the stomach, 5-6.5 in the duodenum and proximal jejunum, 6.5-7.5 in the mid jejunum, and almost up to 8 in the terminal ileum. In the large bowel the pH varies between 6.5 and 8 from the colon ascendens to the sigmoideum. Th is bulk pH will aff ect mainly the solubility of the compound and is also thought to eff ect the ionization that provides a driving force for the regional diff erence in uptake of mainly the uncharged form. Actual transport across the epithelial membrane is aff ected by another pH, the so called microclimate or surface pH(pH=5.5) in the upper small intestine.
Th e pH of the apical solution has a direct impact on the transport experiments using monolayers, since the solution is in direct contact with the membrane and should therefore mimic the microclimate pH. Th e pH on the basolateral side should in all cases refl ect the pH of the extracellular fl uid within the submucosa, which is under direct infl uence of the pH in the blood. Suggested examples for quick evaluation of the pH eff ect (apical/basolateral) on transport in diff erent regions of the intestine include: For weak acids, e.g., salicylic acid, the dependency on a pH gradient becomes complex since both the passive diff usion and the active transport process will be dependent on the proton concentration in the apical solution and a lowering of the pH from 7.4 to 6.5 will increase the apical to basolateral transport more than 20-fold. Similarly, for weak bases such as alfentanil or cimetidine, a lowering of the pH to 6.5 will decrease the passive transport towards the basolateral side. Th e transport of the ionisable compound will, due to the pH partition hypothesis, follow the pKa curve. In an early screening situation when the transport process is unknown, it can be diffi cult to distinguish a passive asymmetric uptake or effl ux due to the pH eff ect on ionization from a true carriermediated uptake or effl ux. Th e following assays are therefore suggested:
If screening for general intestinal absorption is equal • to pH gradient system, only report to projects Apical to Basolateral direction If screening for carrier-mediated transport in any • direction is equal to both a nongradient and a pH gradient system should be used and bidirectional transport data should be reported.
b) Solubility and Bovine Serum Albumin (BSA)
Solubility data are vital in order to improve the quality from the biological assays. Optimizing the permeability measurements to avoid adsorption to plastic, fi lters or accumulation within the cell monolayer seems highly relevant for increasing the predictivity of the screening model in early screening in the determination of permeability values. To perform high-quality permeability measurements, using a cell culture-based model, a limit for low solubility has to be drawn. If the drug is not soluble within the experimental system then the data will be of low quality and aff ect the recovery estimates from the permeability assay. Th e solubility limit to be set is dependent upon several factors, e.g., analytical, enzymatic and whether (or not) transporters are involved. Th erefore, a balance between solubility, analytical and permeability issues must be considered before conducting a large number of assays with lipophilic drugs. Th e eff ect of the presence of BSA will be determined by both the protein binding capacity of the drug to be tested and its intrinsic permeability, i.e., high protein binding and high permeability values will increase the response to the presence of BSA in the basolateral chamber BSA used to increase sink conditions and to reduce the adsorption phenomenon. However, there seems to be a concentrationdependent eff ect of BSA, which has been tested between 0 to 4 %.
MECHANISTIC USE OF CELL MODELS
For the evaluation of a possible relationship between the molecular structure of a potential candidate and its transport abilities to cross the epithelial membrane of the gut, the mechanism or route of transport must be known. During the lead optimization phase -when many mechanistically based studies are performed -the cell culture-based models can also be used with great confi dence (18) .
PARACELLULAR PATHWAY (19)
Compounds are not effi ciently absorbed due to the small available absorptive area and the restriction by tight junctions. CACO-2cells possess lower permeability towards polar molecules than does the small intestine invivo because the monolayer has a much smaller eff ective surface area than the small intestine villi, due to the tight junctional resistance (20) . Th e paracellular pathway, between the epithelial cells, is both size-(molecular weight, volume) and chargedependent. Th e molecular weight cut-off seems to be around 300 g mol-1 for the CACO-2 cell monolayer, which shows the more colonic nature of the CACO-2 monolayer model. (20) Molecules with a large molecular weight or size are confi ned to the transcellular route and its requirements related to the hydrophobicity of the molecule. Th e transcellular pathway has been evaluated for many years and is thought to be the main route of absorption of many drugs, both with respect to carriermediated transport and passive diff usion. Molecules with a large molecular weight or size are confi ned to the transcellular route, transcellular pathway suggested for proteins and peptides is the transcytotic pathway, which involves a receptor-mediated endocytosis in CACO-2 cells.
TRANSCELLULAR PATHWAY
CARRIER-MEDIATED TRANSPORT (21), (22), (23)
Transporters like aminoacid and oligopeptide-carriers (peptide transporters PepT1 and PepT2) are involved in the absorption process of pharmaceutical drugs. Th e organic anion transporters (OAT) and PepT1 is expressed in the cell lines of CACO-2 and HT-29.Cell lines, such as the CACO-2 and MDCK cells have been used frequently to study diff erent transporters in the GI tract. Th ese cell lines have been evaluated for transport both in absorptive and secretory direction, and in addition also been transfected with specifi ed transporter systems of interests to yield new clones or co-cultures.
APPLICATION OF CELL MONOLAYERS AND INTEGRITY MEASUREMENTS
I. Evaluation of Metabolism During Transport (25) Cell culture models can be used to evaluate the im-• portance of metabolism in gut membranes, both with respect to oxidative metabolism via the Cytochrome P450system and Phase-2 reactions CACO-2 model can in fact serve as an excellent • model to investigate both permeation and fi rst-pass metabolism.
II. Evaluate the toxicity of compounds; III. Evaluate the toxicity of excipients in formulations; IV. Establish test solutions for optimal screening; and V. Evaluate formulations containing enhancers of intestinal permeability (26) . (27) Reduce the time and cost to select potential candi-• dates as well as to complement the biological screening and optimization processes because there is no need to synthesize compounds. 
COMPUTATIONAL MODELS FOR PREDICTION OF INTESTINAL PER-MEABILITY
CONCLUSION
Cell lines are well suited as high capacity screening models, biopharmaceutical assessments (like AD-MET, potency properties), and for mechanistic evaluation of transport mechanisms useful in pre clinical and clinical phases of the drug discovery. Cell lines with emphasizing on the CACO-2 models form cost eff ective, less time consuming, quick and easy invitro methods generates high throughout, reliable and reproducible data. Several computational and mechanistic models are commercially available for prediction of intestinal permeability by which, one can predict absorption of drugs in human GIT.
